These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29378722)

  • 1. Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis.
    Britt NS; Ritchie DJ; Kollef MH; Burnham CA; Durkin MJ; Hampton NB; Micek ST
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Pseudomonas aeruginosa isolates from patients with urinary tract infections during antibiotic therapy.
    Horii T; Muramatsu H; Morita M; Maekawa M
    Microb Drug Resist; 2003; 9(2):223-9. PubMed ID: 12820809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Carbapenem resistance in Pseudomonas aeruginosa isolated from urine cultures: prevalence and risk factors].
    Álvarez-Otero J; Lamas-Ferreiro JL; González-González L; Rodríguez-Conde I; Fernández-Soneira MJ; Arca-Blanco A; Bermúdez-Sanjurjo JR; de la Fuente-Aguado J
    Rev Esp Quimioter; 2017 Jun; 30(3):183-194. PubMed ID: 28440605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for healthcare-associated infection caused by carbapenem-resistant Pseudomonas aeruginosa.
    Tsao LH; Hsin CY; Liu HY; Chuang HC; Chen LY; Lee YJ
    J Microbiol Immunol Infect; 2018 Jun; 51(3):359-366. PubMed ID: 28988663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
    Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
    Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study.
    Khadem T; Stevens V; Holt K; Hoffmann C; Dumyati G; Brown J
    Diagn Microbiol Infect Dis; 2017 Oct; 89(2):146-150. PubMed ID: 28780998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
    Zilberberg MD; Shorr AF
    J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis.
    Liu Q; Li X; Li W; Du X; He JQ; Tao C; Feng Y
    Sci Rep; 2015 Jun; 5():11715. PubMed ID: 26108476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Importance of appropriate carbapenem use to reduce carbapenem--resistant Pseudomonas aeruginosa].
    Furukawa K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():258-64. PubMed ID: 17455627
    [No Abstract]   [Full Text] [Related]  

  • 11. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
    Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Carbapenem Resistance Mechanisms and Its Association with Pseudomonas aeruginosa Infections in the Northwest of Iran.
    Akhi MT; Khalili Y; Ghotaslou R; Yousefi S; Kafil HS; Naghili B; Sheikhalizadeh V
    Microb Drug Resist; 2018 Mar; 24(2):126-135. PubMed ID: 28654368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hospitalized patients with resistant or multidrug-resistant
    Raman G; Avendano EE; Chan J; Merchant S; Puzniak L
    Antimicrob Resist Infect Control; 2018; 7():79. PubMed ID: 29997889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa.
    Pakyz AL; Oinonen M; Polk RE
    Antimicrob Agents Chemother; 2009 May; 53(5):1983-6. PubMed ID: 19273670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland.
    Pobiega M; Maciąg J; Chmielarczyk A; Romaniszyn D; Pomorska-Wesolowska M; Ziolkowski G; Heczko PB; Bulanda M; Wojkowska-Mach J
    Diagn Microbiol Infect Dis; 2015 Nov; 83(3):295-7. PubMed ID: 26341705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection or colonization in a Chinese teaching hospital.
    Zhang D; Cui K; Wang T; Shan Y; Dong H; Feng W; Ma C; Dong Y
    J Infect Dev Ctries; 2018 Aug; 12(8):642-648. PubMed ID: 31958327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk factors for Pseudomonas aeruginosa infections, resistant to carbapenem].
    Ghibu L; Miftode E; Teodor A; Bejan C; Dorobăţ CM
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1012-6. PubMed ID: 21500452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates.
    Lodise TP; Miller C; Patel N; Graves J; McNutt LA
    Infect Control Hosp Epidemiol; 2007 Aug; 28(8):959-65. PubMed ID: 17620244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.